---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-023753"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-05-24T23:59:59+00:00"
generated_at: "2026-06-14T16:07:04.498934+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology acquires Apexigen in ~$16M all-stock deal; CMO resigns

## Summary
- Merger valued at ~$16M enterprise value; implied $0.64 per Apexigen share; exchange ratio 0.1725 PYXS shares per APGN share.
- Pyxis stockholders to own ~90% of combined company; Apexigen stockholders ~10%; deal expected to close mid-2023.
- Adds klinical-stage CD40 agonist sotigalimab (Phase 2) and APXiMAB antibody platform to Pyxis' FACT ADC toolkit.
- Cash runway extended into first half of 2025 per company guidance.
- CMO Jay Feingold steps down effective June 15, 2023; will serve as advisor until successor is named.

## SEC filing metadata
- accession: 0000950170-23-023753
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-05-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/0000950170-23-023753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/pyxs-20230523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-023753
- JSON: https://secwatch.observer/filing/0000950170-23-023753.json
- Plain text: https://secwatch.observer/filing/0000950170-23-023753.txt

## Key facts
- Executive change
  Jay Feingold resigned as Chief Medical Officer at Pyxis Oncology, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On May 24, 2023, the Company announced that Jay Feingold, M.D., Ph.D., will be stepping down from his position as the Company's Chief Medical Officer to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/0000950170-23-023753-index.htm
- Material Agreements
  Pyxis Oncology, Inc. entered into Merger Agreement with Apexigen, Inc. (effective 2023-05-23).
  - Action: entry
  - Agreement: merger
  - Counterparty: Apexigen, Inc.
  - Effective: 2023-05-23
  source text: On May 23, 2023, Pyxis Oncology, Inc., a Delaware corporation (“Pyxis Oncology” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Ascent Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Apexigen, Inc., a Delaware corporation (“Apexigen”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/0000950170-23-023753-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.